Abstract:BackgroundOver the years, the measurement of Glycated Hemoglobin (A1c) has solidified as an important risk marker for pre-diabetic patients and for the diagnosis and control of diabetic patients. The High-Performance Liquid Chromatography (CLAE) method has been adopted in prospective studies such as the DDCT, and international certification by the NGSP is available. In this study, analytical performance metrics including imprecision, correlation, linearity, carryover, and detection of hemoglobin variants were evaluated for the Lifotronic® H100 Plus analyzer from China.MethodsThe results were evaluated following CLSI guidelines on samples within stability, collected according to standardized procedures. For the comparative method, 40 patient samples ranging from 4 to 15.4% were analyzed, and two concentrations of internal quality control material were used for intra-assay (5 repetitions per day) and inter-assay (over five days) imprecision testing. Linearity was assessed using samples at two concentrations, one low (4.5%) and another high (17.2%). For carryover evaluation, low (4.98%), intermediate (9.97%), and high (14.96%) concentrations were assayed in an interleaved manner. Hemoglobin variants found in the studied population were determined using the same method employed in correlation tests (HbS, HbF, HbC, HbE, and HbD).ResultsThe method comparison study revealed a Total Error for decision levels of 5.6%: 2.23% and 6.5%: 1.70%, which were lower than the maximum allowable Total Error of 3.3% (EFLM - EuBIVAS). The difference plot showed that 95% of the results fell within acceptable limits. Positive bias was observed in 7 out of 40 tested samples, predominantly in samples with concentrations above 6,5%, although the medical team assessed it as having no clinical impact. For intra-assay imprecision, the obtained result was 0.86%, and for inter-assay imprecision, it was 0.87%, both deemed acceptable according to the 3.0 % specification proposed by the supplier for the two tested levels.Linearity tests were approved for concentrations proposed by the manufacturer between 3 and 18%, and no carryover was found between samples. All hemoglobin variants previously detected in the comparative method were also identified in the test method without exception, although the specific type of Hb variant was not identified.ConclusionsThe LifotronicTM H100Plus analyzer demonstrated approved analytical performance with some notable observations: positive bias was observed in samples with concentrations above 6,5%, though it was not considered clinically relevant, the throughput of 58 tests per hour could be a limitation for laboratories with high testing volumes and the analyzer detected the presence of Hb variants, although it did not identify their specific types.

Variation in Hemoglobin A1c Linked to Hemoglobin S: Comparison of Analysis Results from ion Exchange Chromatography and an Immunoturbidimetric Method

Comparative Analysis of Glycated Hemoglobin A1c Values Obtained by Three Test Methods in Patients with Variant Hemoglobin

Interference of Hemoglobin Variants with HbA1c Measurements by Six Commonly Used HbA1c Methods.

Interference of hemoglobin variants with HbA1c measurements: comparison of 6 commonly used HbA1c methods with the IFCC reference method

Effects of Hemoglobin (Hb) E and HbD Traits on Measurements of Glycated Hb (HbA1c) by 23 Methods

Evaluation of high performance liquid chromatography (HPLC) pattern and prevalence of beta-thalassaemia trait among sickle cell disease patients in Lagos, Nigeria

Performance Evaluation of the DxC 700 AU Chemistry Analyzer in Hemoglobin A1c Measurement

Short-term Biological Variation of Glycated Hemoglobin-A1 c

Assessing and Evaluating HbS Concentration in Asymptomatic Sickle Cell Patients and Patients With Sickle Cell Crisis Through High-Performance Liquid Chromatography (HPLC) in a Tertiary Hospital in Central India

Presumptive Identification of Clinically Significant Hemoglobin Variants Hb E, Hb S, Hb D in Hb A1c Capillary Electrophoresis

Biological variability of glycated hemoglobin

Performance evaluation of the Hemotype SCTM rapid test for the diagnosis of sickle cell disease

Compound Heterozygous with Hb G-Taipei and Hb Lepore-Boston-Washington: an Unexpected Finding Triggered by HbA1c Measurement

A-045 Analytical and Clinical Evaluation of A1c Test by HPLC - LifotronicTM H100Plus Analyzer - in a Brazilian Clinical Laboratory

Evaluation of effects from hemoglobin variants on HbA 1c measurements by different methods

Long-term Visit-to-Visit Variability in Hemoglobin A1c and Kidney-Related Outcomes in Persons With Diabetes

The Usefulness of Glycated Hemoglobin (HbA1c) in the Detection of Diabetes Mellitus

Assessment of enzymatic method for glycated albumin and its correlation research with the diagnosis of diabetes mellitus

Performance verification of affinity chromatography HPLC in HbA1c detection

Limitations of glycated albumin standardization when applied to the assessment of diabetes patients

Visit-to-visit glycated hemoglobin A1c variability in adults with type 2 diabetes